Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation.

Carbon ions irradiation Chondrosarcoma Mutation status Olaparib PARP inhibitor

Journal

Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 17 04 2019
revised: 04 06 2019
accepted: 18 06 2019
entrez: 18 7 2019
pubmed: 18 7 2019
medline: 18 7 2019
Statut: epublish

Résumé

Chondrosarcoma is a malignant tumor that arises from cartilaginous tissue and is radioresistant and chemoresistant to conventional treatments. The preferred treatment consists of surgical resection, which might cause severe disabilities for the patient; in addition, this procedure might be impossible for inoperable locations, such as the skull base. Carbon ion irradiation (hadron therapy) has been proposed as an alternative treatment, primarily due to its greater biological effectiveness and improved ballistic properties compared with conventional radiotherapy with X-rays. The goal of this study was to characterize the genetic mutations of a grade III chondrosarcoma cell line (CH2879) and examine the cellular responses to conventional radiotherapy (X-rays) and hadron therapy (proton and carbon ions) in the presence of the PARP inhibitor Olaparib. To better understand PARP inhibition, we first analyzed the formation of poly-ADP ribose chains by western blot; we observed an increase in its signal after irradiation, which disappeared on addition of the PARP inhibitor. PARPi enhanced ratio of approximately 1.3, 1.8, and 1.5 following irradiation of cells with X-rays, protons, and C-ions, respectively, as detected by clonogenic assay. The decrease in cell survival was confirmed by proliferation assay. The radiosensitivity of CH2879 cells was associated with mutations in homologous recombination repair genes, such as

Identifiants

pubmed: 31312595
doi: 10.1016/j.jbo.2019.100246
pii: S2212-1374(19)30084-3
pii: 100246
pmc: PMC6609837
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100246

Références

Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Nat Rev Clin Oncol. 2018 Sep;15(9):564-576
pubmed: 29955114
Lancet Oncol. 2015 Feb;16(2):e93-e100
pubmed: 25638685
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1196-203
pubmed: 18207661
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):241-50
pubmed: 10924995
Nucleic Acids Res. 2012 Dec;40(22):11189-201
pubmed: 23066108
EMBO Mol Med. 2009 Sep;1(6-7):315-22
pubmed: 20049735
Eur J Cancer. 2010 Jan;46(1):9-20
pubmed: 19926276
BMC Cancer. 2010 Nov 05;10:606
pubmed: 21050498
Br J Radiol. 2014 Mar;87(1035):20130626
pubmed: 24198199
Oncogene. 2008 Sep 18;27(41):5443-53
pubmed: 18794879
Cancer Lett. 2016 Aug 10;378(2):97-103
pubmed: 27224892
Oncologist. 2008 Mar;13(3):320-9
pubmed: 18378543
Lab Invest. 2003 Jun;83(6):877-87
pubmed: 12808123
Nat Rev Genet. 2017 Oct;18(10):613-623
pubmed: 28649135
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7
pubmed: 17056193
Radiat Oncol. 2016 Sep 22;11(1):126
pubmed: 27659937
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Clin Cancer Res. 2010 Sep 15;16(18):4517-26
pubmed: 20823142
J Clin Oncol. 2008 Aug 1;26(22):3785-90
pubmed: 18591545
Oncogene. 2018 Jan 18;37(3):341-351
pubmed: 28945226
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
Anticancer Drugs. 2011 Aug;22(7):596-606
pubmed: 21051993
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487462
Oncotarget. 2017 Jul 7;8(40):69105-69124
pubmed: 28978184
Front Oncol. 2016 Feb 25;6:30
pubmed: 26942125
Expert Rev Mol Diagn. 2002 Sep;2(5):461-72
pubmed: 12271817
J Surg Oncol. 2016 Oct;114(5):564-569
pubmed: 27760458
Bull Cancer. 2010 Jul;97(7):819-29
pubmed: 20659870
Ann Oncol. 2014 Jan;25(1):32-40
pubmed: 24225019
J Neurosurg. 1999 Sep;91(3):432-9
pubmed: 10470818
Br J Cancer. 2016 Nov 8;115(10):1157-1173
pubmed: 27736844
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Oncotarget. 2016 Nov 29;7(48):79485-79493
pubmed: 27825131
Prog Tumor Res. 2016;43:128-41
pubmed: 27595362
Scientifica (Cairo). 2014;2014:438030
pubmed: 25018892
Sci Rep. 2018 Feb 26;8(1):3664
pubmed: 29483558

Auteurs

Mathieu Césaire (M)

LARIA, iRCM, François JACOB Institute, DRF-CEA, Caen, France.
ENSICAEN, UNICAEN, CEA, CNRS, CIMAP UMR6252, Normandie University, Caen 14000, France.
Centre Francois Baclesse, Radiotherapy Unit, Caen, France.

Utpal Ghosh (U)

LARIA, iRCM, François JACOB Institute, DRF-CEA, Caen, France.
ENSICAEN, UNICAEN, CEA, CNRS, CIMAP UMR6252, Normandie University, Caen 14000, France.
Department of Biochemistry & Biophysics, University of Kalyani, India.

Jean-Baptiste Austry (JB)

LARIA, iRCM, François JACOB Institute, DRF-CEA, Caen, France.
ENSICAEN, UNICAEN, CEA, CNRS, CIMAP UMR6252, Normandie University, Caen 14000, France.

Etienne Muller (E)

Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen, France.
INSERM U1245, Normandy Center for Genomic and Personalized Medicine, Rouen University, Rouen, France.

Francesco Paolo Cammarata (FP)

Institute of Molecular Bioimaging and Physiology, National Research Council - (IBFM-CNR), (PA), Cefalù , Italy.
INFN, Laboratori Nazionali del Sud, Via Santa Sofia 62, 95123, Catania, Italy.

Marilyne Guillamin (M)

IFR ICORE - Flow Cytometry Platform, Normandy University, Caen, France.

Massimo Caruso (M)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.

Laurent Castéra (L)

Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen, France.
INSERM U1245, Normandy Center for Genomic and Personalized Medicine, Rouen University, Rouen, France.

Giada Petringa (G)

INFN, Laboratori Nazionali del Sud, Via Santa Sofia 62, 95123, Catania, Italy.

Giuseppe Antonio Pablo Cirrone (GAP)

INFN, Laboratori Nazionali del Sud, Via Santa Sofia 62, 95123, Catania, Italy.

François Chevalier (F)

LARIA, iRCM, François JACOB Institute, DRF-CEA, Caen, France.
ENSICAEN, UNICAEN, CEA, CNRS, CIMAP UMR6252, Normandie University, Caen 14000, France.

Classifications MeSH